LGND logo

Ligand Pharmaceuticals Incorporated (LGND)

$293.81

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LGND

Market cap

$5.88B

EPS

2.54

P/E ratio

32.3

Price to sales

20.71

Dividend yield

--

Beta

1.209388

Price on LGND

Previous close

$301.71

Today's open

$300.26

Day's range

$291.61 - $302.02

52 week range

$175.89 - $326.63

Profile about LGND

CEO

Todd C. Davis

Employees

47

Headquarters

Jupiter, FL

Exchange

NASDAQ Global Market

Shares outstanding

20002986

Issue type

Common Stock

LGND industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LGND

Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy

Ligand Pharmaceuticals earns a BUY rating, driven by robust royalty growth and the accretive XOMA acquisition. Filspari's 85% YoY royalty growth and new FSGS indication position it as LGND's leading earnings driver. XOMA's $12.3M Q3 royalty contribution and deep pipeline diversify LGND's revenue and future catalysts.

news source

Seeking Alpha • Nov 4, 2026

news preview

Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Melanie Herman - Executive Director of Investor Relations and Financial Planning & Analysis Todd Davis - CEO & Director Octavio Espinoza - Chief Financial Officer Lauren Hay Paul Hadden - Senior Vice President of Investments & Business Development Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Glen Santangelo Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Ligand Third Quarter Earnings Call.

news source

Seeking Alpha • Oct 30, 2026

news preview

What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call

Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchase of XOMA Royalty. The company also raised its full-year adjusted diluted earnings-per-share outlook while maintaining its revenue guidance.

news source

MarketBeat • Oct 29, 2026

news preview

Ligand Reports Third Quarter 2026 Financial Results

Third-quarter royalty revenue up  51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Ligand to Participate in November Investor Conferences

JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Global Healthcare Conference.

news source

GlobeNewsWire • Oct 27, 2026

news preview

Ligand to Host Investor Day on December 8, 2026

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.

news source

GlobeNewsWire • Oct 15, 2026

news preview

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.

news source

GlobeNewsWire • Sep 24, 2026

news preview

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.

news source

GlobeNewsWire • Sep 22, 2026

news preview

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.

news source

PRNewsWire • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ligand Pharmaceuticals Incorporated

Open an M1 investment account to buy and sell Ligand Pharmaceuticals Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LGND on M1